BridgeBio Pharma Revenue 2018-2024 | BBIO

BridgeBio Pharma revenue for the twelve months ending September 30, 2024 was $0.218B, a 2209.77% increase year-over-year.

  • BridgeBio Pharma annual revenue for 2023 was $0.009B, a 88.02% decline from 2022.
  • BridgeBio Pharma annual revenue for 2022 was $0.078B, a 11.38% increase from 2021.
  • BridgeBio Pharma annual revenue for 2021 was $0.07B, a 745.14% increase from 2020.

BridgeBio Pharma Revenue 2018-2024 | BBIO

  • BridgeBio Pharma annual revenue for 2023 was $0.009B, a 88.02% decline from 2022.
  • BridgeBio Pharma annual revenue for 2022 was $0.078B, a 11.38% increase from 2021.
  • BridgeBio Pharma annual revenue for 2021 was $0.07B, a 745.14% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$24.9B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M